Articles related to STROKE

In this pivotal trial, apixaban, when used for subclinical atrial fibrillation, demonstrated a 0.63 hazard ratio for stroke or systemic embolism compared to aspirin, indicating a significant reduction in stroke risk at the expense of increased bleeding risk.

The study underscores the potential of dual antiplatelet therapy in reducing the risk of recurrent stroke. However, it also highlights the need for careful patient selection due to the slightly increased risk of moderate-to-severe bleeding.

Recent studies have indicated a potential increase in stroke risk among seniors, particularly those aged 85 and older, who receive both COVID-19 and influenza vaccines simultaneously. This finding has sparked a renewed focus on the safety of administering multiple vaccines at the same time.

A recent study involving 4,400 participants revealed that two major statins—rosuvastatin and atorvastatin—are equally effective at reducing heart attacks, strokes, and all-cause deaths. However, it was found that the rosuvastatin group was more likely (7.2%) to develop type 2 diabetes than the atorvastatin group (5.3%).

Accelerate your understanding of thrombotic disease treatment developments; delve into the Fast Track designation of milvexian, a promising oral factor XIa inhibitor.

Promising Discovery: Existing Drugs Could Be Repurposed for First Treatment of Dementia-Linked Strokes Clinical trials reveal the potential of two commonly used cardiac drugs, isosorbide mononitrate and cilostazol, to serve as novel treatment options for lacunar strokes, a leading cause of dementia. Key Points: “Now we understand more about what is triggering these small vessel strokes to attack the brain, we’ve been able to focus our efforts on treatments that can put a halt to this damage…as these drugs are already widely available for other circulatory disorders, and inexpensive, it shouldn’t take too long to move our findings from research into everyday clinical practice.” Professor Joanna Wardlaw of the University of Edinburgh and UK Dementia Research Institute